NCT03271632Not yet recruitingPhase 1/2
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 27 Aug 2017
- Start date
- 31 Dec 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT03271632
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 20
- From 31 Dec 2026 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Previous related CAR-T cell therapy Any uncontrolled active medical disorder that would preclude participation
Other illness
- Uncontrolled active infection
- Active hepatitis B or hepatitis C infection
- HIV infection
Other
- Pregnant or lactating women
Who the study is looking for
- Male and female subjects with surface antigen confirmed multiple myeloma with no available curative treatment options (including autologous or allogeneic SCT).
- Complete remission (CR) cannot be achieved after at least 4 prior combination therapy regimens.
- MM in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid diseases, or lack of available donor.
- Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year).
- Relapsed after prior autologous or allogenic SCT MM patients with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT.
- Residual disease after primary therapy and not eligible for ASCT
- Expected survival \> 12 weeks
- Creatinine \< 2.5 mg/dl
- ALT (alanine aminotransferase)/AST (aspartate aminotransferase) \< 3x normal
- Bilirubin \< 2.0 mg/dl
- Any relapse after prior SCT is eligible regardless of other prior therapy
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
- Voluntary informed consent is given
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.